# J.P.Morgan

## **AIA Group Ltd**

Shareholder return ≈ f(growth, cash flow and capital); acceleration outlook for these three variables

AIA Group surprised the market with strong FY14 results that beat across the board. In our view, the current share price does not fairly capture AIA's: (1) growth acceleration outlook in China/Hong Kong/Malaysia ( $\sim$ 50% of NBV); (2) strong free cash flow re-rating momentum; (3) strong balance sheet position for a better capital deployment outlook; and (4) similar comp valuation level to Chinese insurers. We believe AIA is entering a new virtuous cycle (i.e., growth  $\rightarrow$  free cash flow  $\rightarrow$  capital deployment), with upscale driving shareholder returns. Thus, we see current levels as an opportunity.

- Growth king. AIA's NBV has accelerated by 2.8x since the IPO (~US\$0.7B in 2010 vs. ~US\$1.8B in 2014), appealing to equity investors as a "growth stock." With an outlook for acceleration in the insurance (protection) market in China, we expect AIA's value growth acceleration to drive upward revisions of NBV expectations. We highlight that China Life has similar (or higher) valuation multiples despite its single-digit NBV growth outlook. Contrary to concerns about local currency weakness and limited upside due to a maturing market, AIA's strong integration synergies following its inorganic expansion into Malaysia and strong sales demand for high-end protection/retirement sales growth in Hong Kong are enough additional drivers to revise up market NBV expectations, in our view.
- Free cash flow king. AIA's free cash flow block from in-force policies is expected to be re-rated to ~US\$140B (+47%) over the next three years (vs. US\$95B/US\$65B in Nov-14/Nov-11) with a lowered new business strain on total NBV of up to ~80% in 2017E from ~114%/~101% in 2010/2013.
- Capital king. Thanks to the widening free cash flow and strong NBV growth, we expect AIA's progressive dividend policy (~15% DPS increase p.a.) to be aggressive gradually. As Asia-ex countries are adopting stricter solvency standards, we cannot rule out large capital deployment in the ASEAN market with a large-scale increase outlook.
- Reiterate OW. Our Dec-15 PT of HK\$55 is derived via a multi-stage NBV growth model that yields an implied blended P/EV of 2.1x and a blended new business multiple of 19x for the group. Risks include: (1) slowing NBV growth momentum; (2) longer-than-expected financial market volatility in Asia-ex; and (3) a weaker-than-expected business turnaround in Malaysia.

## Overweight

**1299.HK, 1299 HK** Price: HK\$47.35

Price Target: HK\$55.00 Previous: HK\$51.00

Hong Kong Insurance - Life

**MW Kim** AC (852) 2800-8517

mw.kim@jpmorgan.com

Bloomberg JPMA MKIM <GO>

Josh Klaczek

(852) 2800-8534

josh.klaczek@jpmorgan.com

J.P. Morgan Securities (Asia Pacific) Limited



## Comp valuation: AIA Group vs. Chinese insurers

Х	P/EV (FY15E)	P/BV (FY15E)
AIA Group	1.8	2.3
China Life-H	1.8	2.8
CPIC-H	1.3	2.5

Source: J.P. Morgan estimates, Bloomberg. As of 2-Mar-15.

1Q15 NBV release: Mid-April 2015

#### AIA Group Ltd (Reuters: 1299.HK, Bloomberg: 1299 HK)

\$ in mn, year-end Nov	FY13A	FY14A	FY15E	FY16E	FY17E
EPS (\$)	0.24	0.29	0.32	0.37	0.41
EPS growth	(6.3%)	22.2%	11.6%	15.7%	11.2%
BVPS (\$)	2.06	2.57	2.68	2.97	3.28
DPS (\$)	0.05	0.06	0.07	0.09	0.10
EV per share (\$)	2.82	3.09	3.37	3.70	4.09
NBV per share	0.12	0.15	0.18	0.20	0.24
P/E (x)	26.0	21.3	19.0	16.5	14.8
P/BV (x)	3.0	2.4	2.3	2.1	1.9
P/EV	2.2	2.0	1.8	1.6	1.5
Dividend Yield	0.9%	1.1%	1.2%	1.4%	1.6%
ROE	11.0%	12.4%	12.2%	13.1%	13.2%

Source: Company data, Bloomberg, J.P. Morgan estimates.

Company Data	
Shares O/S (mn)	12,006
Market Cap (\$ mn)	73,301
Market Cap (\$ mn)	73,301
Price (HK\$)	47.35
Date Of Price	02 Mar 15
Free Float(%)	-
3M - Avg daily vol (mn)	22.90
3M - Avg daily val (HK\$ bn)	1.01
3M - Avg daily val (\$ mn)	129.9
HSI	24,823.29
Exchange Rate	7.76
Price Target End Date	30-Dec-15

See page 17 for analyst certification and important disclosures, including non-US analyst disclosures.

J.P. Morgan does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

#### Key catalysts for the stock price:

• Strong growth potential from low insurance penetration across the region

- Strong positioning in the agencybased protection-type market (i.e., healthcare insurance)
- High visibility of future cash flow generation from existing policies with strong balance sheet and conservative actuarial assumptions

#### Downside risks to our view:

- Slowing NBV growth momentum

   StrongerLonger-than-expected financial market volatility in Asiayield curve
- ex
   A longer-than-expected business turnaround in
- A longer-than-expected business turnaround in Malaysia

#### Upside risks to our view:

- Stronger-than-expected equity market/steepening of yield curve
- Fast growth of protection insurance demand in ASEAN
- Higher penetration of Islamic life insurance market (i.e., family Takaful) in Malaysia/Indonesia

Key financial metrics	FY14A	FY15E	FY16E	FY17E
Net written premium (LC)	17,052	19,017	21,114	23,815
Net earned premium (LC)	17,052	19,017	21,114	23,815
Net earned premium growth	9%	12%	11%	13%
Investment profit (LC)	5,570	6,201	6,655	7,227
Incurred loss (LC)	(16,804)	(17,781)	(19,214)	(21,434)
Underwriting expense (LC)	(3,775)	(4,155)	(4,603)	(5,180)
Underwriting income (LC)	(3,527)	(2,919)	(2,703)	(2,798)
Net income (LC)	3,450	3,844	4,439	4,934
Group embedded value (LC)	37,153	40,340	44,309	48,922
Life embedded value (LC)	37,153	40,340	44,309	48,922
New business value (LC)	1,845	2,172	2,447	2,861
Solvency margin	427%	410%	404%	397%
Investment yield	6%	6%	6%	6%
DPS (LC)	0.06	0.07	0.09	0.10
BVPS (LC)	2.57	2.68	2.97	3.28
ROA	2%	2%	2%	2%
ROE	12%	12%	13%	13%
Payout ratio	22%	23%	23%	24%
Key model assumptions	FY14A	FY15E	FY16E	FY17E
Metric #1: EVPS (US\$)	3.09	3.37	3.70	4.09
Metric #2: NBV growth (%)	24%	18%	13%	17%
Metric #3: EPS growth (%)	22%	12%	16%	11%

Source: Company and J.P. Morgan estimates.


Sensitivity analysis	EPS	
Sensitivity to	FY15E	FY16E
1% chg net earned premium growth	-0.3%	-0.2%
1% chg in investment yield assumption	14.2%	13.2%
1% chg in loss ratio assumption	-3.7%	-3.6%
1% chg in expense ratio assumption	-3.7%	-3.6%

Source: J.P. Morgan estimates.

#### Valuation and price target basis

We assign AIA Group a Dec-15 PT of HK\$55 per share by incorporating a multi-stage growth model to project NBV for each geographical market separately, which yields an implied blended P/EV of 2.1x and a blended new business multiple of 19x for the group.

#### NBV by market segment (FY14)



Source: Company Reports

JPMe vs. consensus, change in estimates						
EPS (LC)	FY15E	FY16E				
JPMe old	0.32	0.38				
JPMe new	0.32	0.37				
% chg	1%	-1%				
Consensus	0.30	0.34				

Source: Bloomberg, J.P. Morgan estimates.

#### **Comparative metrics**

	CMP	Mkt cap	P/E (x	)	P/EV (x)		P/BV (x	()	YTD
	(LC)	(\$M)	FY14E/A	FY15E	FY14E/A FY15E		FY14E/A FY15E		stock perf.
AIA Group	47.4	73,545	21	19	2.0	1.8	2.4	2.3	9.7
Ping An-H	86.4	101,833	15	13	0.9	0.9	2.7	2.0	9.2
China Life-H	33.3	155,602	23	19	2.0	1.8	3.1	2.8	9.4
CPIC-H	40.3	48,677	24	18	1.5	1.3	2.7	2.5	2.2
New China Life-H	43.2	22.809	26	16	1.2	1.1	2.5	2.1	10.3

Source: Bloomberg, J.P. Morgan estimates. Prices are as of 2 March 2015.



## Investment thesis

Contrary to market concerns about weak currency and volatile macro conditions in ASEAN and the limited potential for NBV growth surprises from its record NBV base, AIA Group surprised the market with strong FY14 results that beat across the board (please see our note, <u>AIA Group Ltd: First cut at 2H FY14 results- Beat across the board</u>). In our view, the current share price does not fairly capture AIA's: (1) growth acceleration outlook in China/Hong Kong/Malaysia (~50% of NBV); (2) free cash flow re-rating momentum from the 28M individual in-force policies (undiscounted basis: ~US\$95B in Nov-14 vs. ~US\$69B in Nov-11); (3) strong balance sheet position as a share price driver; and (4) similar comp valuation level to Chinese insurers. We believe AIA is entering a new virtuous cycle (i.e., growth → free cash flow → capital deployment), with upscale driving shareholder returns.

### I. Growth king

#### NBV acceleration of 2.8x since 2010

AIA shares appeal to equity investors as a "growth stock." Its US\$667M in NBV in 2010 has increased to ~US\$1.845M over the last five years. Within Asia, the company's growth profile (or growth drivers) has changed largely across the region.

Based on NBV, for the last five years: (1) China and Malaysia have become important countries for growth; (2) growth exposure to Thailand has continuously declined; (3) Hong Kong has regained its position as a growth country; and (4) Korea has seen the least dynamic geographic exposure, with a lowered contribution.

Figure 1: AIA Group: NBV by market segment





Figure 2: AIA Group: Operating profit after tax by market segment



Source: Company reports. Note: Prior to HK reserve and capital requirement adjustments and unallocated group office expense.

Source: Company reports. Note: The group corporate center is not included here.

In its earnings presentation, the company clearly identified the following long-term structural growth drivers in Asia: (1) large population growth (or demographics); (2) rapid urbanization; (3) rising income and wealth; (4) low social welfare; and (5) low private coverage (or a substantial life protection gap). Given that the company is clearly in the leading position in each geographical region, the outlook for overall long-term NBV acceleration on the back of both product margin and volume makes sense to us. Our NBV projections for the next 20 years in each country partially factor in these expectations, with ~10.5% NBV growth p.a. for the first 10 years (2015E-2024E) and ~4.9% NBV growth p.a. for the following 10 years (2025E-2034E).

#### Near-term NBV upside potential from China/Hong Kong/Malaysia

The company's overall reported FY14 NBV margin was ~49.1% (after HK reserves, capital requirements and group office expense adjustments) vs. 48.9% in 2013. Thus, a key question is whether there is more room to improve NBV margins from the current high base and where potential areas for positive NBV contributions are.

In particular, the market seems to be concerned about China, Hong Kong and Malaysia due to disagreements about the outlook for healthcare market acceleration. These stem from the short track record and record NBV margin (China), high sales base and limited market growth outlook as the market matures (Hong Kong) and local currency weakness and smaller-than-expected APE growth (Malaysia).

We expect price momentum to be driven by a buildup of expectations for future NBV growth momentum following the market acceleration in China, more evidence of AIA's strong integration synergy following the inorganic expansion into Malaysia, and strong sales demand for high-end protection/retirement sales growth in Hong Kong.

Table 1: AIA Group: NBV by market segment US\$ in millions. %

_	2012				2013			2014		
•		NBV			NBV			NBV		
	NBV	margin	APE	NBV	margin	APE	NBV	margin	APE	
Hong Kong	366	58.4%	604	468	57.6%	781	619	62.3%	952	
Thailand	287	53.9%	532	319	56.3%	565	361	63.2%	572	
Singapore	220	65.1%	339	269	67.3%	400	299	61.2%	489	
Malaysia	69	46.0%	151	120	37.8%	319	161	50.1%	320	
China	124	57.5%	215	166	66.4%	249	258	83.1%	311	
Korea	68	28.5%	237	91	26.8%	338	82	21.7%	380	
Other Markets	167	27.0%	618	220	32.0%	689	212	31.3%	676	
Subtotal	1,301	47.8%	2,696	1,653	48.9%	3,341	1,992	53.1%	3,700	

Source: Company reports. Note: Prior to HK reserve and capital requirement adjustments and unallocated group office expense.

#### Additional key areas for NBV surprises

We also look at areas likely to lift NBV (or growth) expectations and identify the consensus revision candidates in China and Korea.

#### China

Given the view that the current NBV margin is too high, our projections do not factor in further margin improvement in China. As shown in China Life's 2013 corporate day presentation, profit for many life insurers in China depends largely on investment spread margin (= investment return - funding cost). Despite fast demand increases for critical illness (CI) insurance or healthcare coverage, particularly in tier 1 cities, we believed investment spread margin would account for 50%+ of profit in China. In addition, the company's premium income for 2014 was only about Rmb11B (vs. ~Rmb331B for China Life and ~Rmb174B Ping An Life).

Figure 3: China life insurance industry: Premium Income (2014) Rmb in billions





Figure 4: China life insurance industry: Premium income breakdown by product



Source: Company reports.

Source: CIRC.


However, following the company's further disclosures on its AIA China operations during this year's earnings presentation, we have begun to think that **further NBV** margin improvement (or better-than-expected NBV growth) in China is possible.

First, the healthcare insurance market is accelerating, particularly in tier 1 cities (i.e., structural market expansion), following increases in household wealth and risk awareness. Considering AIA's agency-based distribution model, we believe the company could capture the acceleration in the protection market's momentum faster than the market expects by selling higher medical coverage riders.

Second, we think agency recruiting and retention trends may be stronger than expected, driving better productivity. According to the company's disclosures, overall FY14 NBV/agent is 3.0x higher than industry peers'. This would mean that its agency income level is likely to be much higher than peer insurers'. Thus, we cannot rule out a virtuous cycle of large headcount increases building the agency force and productivity improvement potential driving higher NBV growth momentum.


In conclusion, although we expect China to be a Top 3 NBV contribution country within AIA Group by the end of 2016, replacing Singapore, the fast market acceleration, further product mix shift into protection (or healthcare), and scale/productivity increases in the agency channel could mean that China NBV acceleration is possible even in 2015 or mid-2016, exceeding AIA Singapore and driving upward estimate revisions.

Figure 5: AIA China: Sources of statutory earnings (2014)



Source: Company reports.

Figure 6: China Life: Investment spread in three sources of statutory earnings



Source: Company reports.

#### Korea

Unlike its strong NBV growth in China and other markets, the company has posted subpar performance in Korea. AIA Korea's ~8% group NBV contribution in 2010 declined to ~4% in 2014, with only ~37% NBV growth for the last five years. During the sales period, the group's/China's NBV increased by 214%/438%. However, given that AIA still allocates ~7.8% of group capital to Korea, it is clearly an NBV/ROE dilution area when valuing the company.


Although management remains optimistic about Korea's operational outlook, we believe the Korea operation is not likely to turn around near-term without any consideration of changing its positioning (or formation) in Korea or scaling down. Rather, we believe Korea will serve as a "value overhang" for the group.

Figure 7: AIA Group: Operating return on allocated equity by segment



Source: Company reports.

Figure 8: AIA Group: NBV comparison by market segment US\$ in millions




Source: Company reports.

To be fair, we also believe the Korea life insurance market remains attractive due to: (1) demographics (aging population); (2) low protection coverage compared to household wealth levels; (3) high inheritance tax rates (up to  $\sim$ 50%); and (4) favorable changes in cancer claim patterns.


Overall top life insurers like Samsung Life (SLI) deliver >7-10% protection APE growth y/y, on average. The protection product is largely skewed toward whole life (purely covering the death benefit) instead of healthcare under the extended life expectancy. Following the first retiring of Baby Boomers, upside still exists in terms of retirement market growth. Finally, the corporate pension reserve has started to generate positive fee growth since this market became mandatory in 2012, with a 60-70bp spread margin outlook longer-term. From that perspective, the market characteristics seem to fairly match AIA Group's growth strategy, in our view.

Figure 9: Korea life insurers: Claim loss ratio trend



Source: Korea Life Insurance Association (KLIA).

Figure 10: SLI: Quarterly APE breakdown by product Won in billions



Source: Company reports.

However, we see limitations for AIA in the Korea market due to its weak distribution channel and legacy book in protection coverage. While major Korea life insurers have legacy on their old high-yield guarantee products (i.e., negative investment spread), AIA seems to have a large legacy book on its old protection coverage (i.e., negative morbidity margin). In addition, business penetration into whole life has been limited by the limited exclusive agency size, in our view. Given that distribution's bargaining power is shifting from the intermediaries to the manufacturers (or insurers) in the way of lowering commission rates, without strengthening the exclusive agency forces, this should remain a challenge area for group NBV creation in terms of capital allocation, in our view. In conclusion, we believe any changes to the company's positioning in Korea should drive another NBV revision case from the current low base of expectations.

#### Other markets


We believe AIA's strong NBV growth momentum across the region for the last few years provides a clear anchor for future growth expectations. However, considering the company's overcapitalized balance sheet and stricter RBC introduction across the region, we cannot rule out the potential for large capital releases in the ASEAN market to capture the inorganic growth opportunity. This would drive another NBV revision for the company. We discuss this agenda in the following section, under the subtitle "stricter solvency region and better capital deployment outlook."

### II. Free cash flow king

#### Strong free cash flow growth from in-force policies

Despite its large scale and market concerns about limited potential for scale increases due to its high base, the company has strongly improved fundamentals since its 2010 IPO, leveraging its new customers and ~28M existing individual policyholders. As a result, its undiscounted after-tax distributable earnings from in-force policies re-rated to ~US\$95B in Nov-14 from ~US\$69B in Nov-11. Based on our projections, the free cash flow block from in-force policies should be re-rated to ~US\$140B (+47%) over the next three years, supporting an earnings re-rating and better capital consumption for value growth.

Figure 11: AIA Group: Projected after-tax distributable earnings from in-force policies US\$ in billions



Source: Company reports. Note: The above free cash flow projection is based on undiscounted numbers (without consideration of the time value of money). On a discounted basis, total aggregated free cash flow was ~US\$21.3B in 2011 and ~US\$29.4B in 2014.




#### **Key drivers of free cash flow acceleration for the next couple of years**

Reviewing the last four years' free surplus/EV movement, we have identified key factors possibly driving the widening of FCF for the next couple of years.

First, the company's payback period on new policies has shortened to 4.0 years from 5.0 years in 2010. Management explained in its earnings presentation that this is due to product mix changes (i.e., A&H protection sales increases), lower upfront commissions (or a lower DAC portion) and re-pricing effects. In our view, it clearly suggests mortality/morbidity profit base increases, a better-than-expected persistency ratio outlook (due to increased backloading commission size) and a positive operational experience outlook following rapid adjustment to the pricing error.


Next, overall NBV strain (or new business investment) on total NBV declined to up to 90% of NBV as of 2014 due to economies of scale and product mix changes. Based on our projections, overall new business strain on total NBV will decline to ~80% by 2017. This would mean that AIA's free surplus generation would accelerate with a lowered cash consumption outlook driving an earnings re-rating from its in-force policies.

Figure 12: AIA Group: New business strain as % of NBV US\$ in millions, %



Source: Company reports and J.P. Morgan estimates.

Figure 13: AIA Group: Movement on free surplus US\$ in millions



Source: Company reports.  $^{\star}$  Free Surplus as Beginning of Period is post-Citibank upfront payment.

#### Review of economic assumptions

Next, the question is whether the long-term cash flow assumption is conservative enough. The company has consistently delivered positive operational variance on its EV movement, with a 90%+ VIF-to-NAV conversion. The increasing returns and capital efficiencies of new business also suggest adequate pricing practices with agile pricing error adjustments.

Thus, we review AIA's economic assumptions and compare them to those of multinational competitor U.K. Prudential Asia. In our view, overall risk discount rate and investment return assumptions (compared to 10-year bonds) look conservative (or reasonable). Thus, overall economic assumption variance is not expected to dent free cash flow assumptions much, in our view.

Table 2: AIA Group vs. U.K. Prudential: Economic assumptions comparison

%

Risk discount rate	Hong Kong	Singapore	Thailand	Malaysia	China	Korea
AIA Group	7.0	6.8	9.0	8.8	9.8	9.5
Prudential						
New Business	4.3	4.3	10.6	6.6	10.6	6.8
VIF	4.2	5.0	10.6	6.6	10.6	7.1
Difference	2.8	1.8	-1.6	2.2	-0.9	2.4
(=AIA- Pru's VIF)						
Investment return	Hong Kong	Singapore	Thailand	Malaysia	China	Korea
AIA Group	2.5	2.2	3.6	4.2	3.7	3.6
Prudential	2.6	2.3	3.8	4.1	4.1	3.2
Difference	-0.1	-0.1	-0.2	0.1	-0.4	0.4
(=AIA- Pru)						
10-year bond yield (31-Dec-14)	2.1	2.3	2.8	4.1	3.6	2.6

Source: Company reports. Note: AIA numbers are based on FY14 annual report disclosures. U.K. Prudential Asia numbers are based on 1H14 reports.

### III. Capital king


#### Progress and sustainable dividend policy with upside

Unlike other insurers in Asia-ex, AIA has a progressive dividend policy that generally increases DPS by 15% p.a., regardless of bottom-line volatility. Reflecting this practice, overall market expectations for DPS remain conservative. However, during FY14 reporting, the company increased its DPS by 18% y/y, to HK\$50cents from HK\$42.55cents. Although we remain at 15% DPS increases p.a. for FY15E-17E, we believe there is room for better-than-expected DPS declarations, supporting better shareholder returns, considering the strongly improved capital position and solid earnings outlook.

#### 12%+ RoEV/ROE outlook

The company's solvency ratio has continuously improved since 2011 on the back of widened valuation gains on its AFS bonds, solid earnings growth and ~US\$2B in debt capital raises. Despite large increases in the capital buffer (or shareholders' funds), the company has managed its RoEV and ROE well above 12%, with efficient capital allocation into growth countries like China (organic growth) and Malaysia (inorganic growth). Considering the condition of its balance sheet, we expect AIA to allocate more capital to capture growth in the region, generating solid ROE/RoEV.





Source: Company reports and J.P. Morgan estimates. Note: We exclude the variance in economic assumptions and capital movement in this calculation.

Figure 15: AIA Group: Solvency ratio trend for AIA Co.



Source: Company reports

#### Stricter solvency region and better capital deployment outlook

In addition to potential DPS upside and a stable ROE generation outlook, the key question is whether the company really needs keep substantial capital on the balance sheet without large capital deployments to shareholders near-term. In our view, AIA's strong balance sheet should serve as a "new" share price catalyst for the next couple of years.

We want to put the solvency II framework into perspective. Starting from Singapore and Korea in 2016, a gradual adoption of strengthened solvency standards across Asian countries suggests further capital-raising potential, particularly for insurers owned by local banks selling single savings-type products.

In our view, similar to HSBC's series of insurance business disposals across EM, many local banks in the region will consider disposing of insurance operations to avoid additional capital burdens (or lower group ROE) and/or to turn passive in insurance underwritings. In addition to Singapore, Thailand and Indonesia are countries where AIA could increase scale with better capital allocation, in our view.

In short, AIA Group's ample experience in each country and strong balance sheet position suggest strong potential for scale increases and/or better deployment of its excess capital going forward. (For details, see <u>Asia Insurance: Beyond 3Q: Positive Outlook on Several Fronts</u>, dated 25 November 2014.)

**Table 3: AIA Group: Credit ratings** 

	Rating agency	Financial Strength rating	Counterparty Credit rating	Latest rating date
AIA Co.	S&P	AA- / Stable /	AA- / Stable /	22-Jul-14
	Moody's	Aa3 / Stable	NA	29-Jan-15
AIA International	S&P	AA- / Stable /	AA- / Stable /	22-Jul-14
	Moody's	Aa3 / Stable	NA	29-Jan-15
AIA Group Limited	S&P	NA	A / Stable / A-1	22-Jul-14
•	Moody's	NA	A3 / Stable	29-Jan-15

Source: Company reports.

## Estimate revisions

## **Earnings**

We fine-tune FY15E/16E earnings and introduce FY17E earnings. Our process factors in the company's recent operations and investment trend. First, considering the shortened pay period and/or lower DAC, we revise down sales commission expense. Second, following the company's scale growth and better expense control, we also reduce overall expenses. Third, on the investment side, reflecting the lower long-term bond yield trend across the region, we lower our investment yield assumption on interest-bearing assets. Finally, we normalize realised and unrealised gains (losses) up to ~US\$2B from FY13's low base (~US\$0.6B). The company's average realized and unrealised gains (losses) p.a. since 2007 was ~US\$4.3B.


Table 4: AIA Group: FY15/16 earnings revisions

US\$ in millions

		FY15E		FY16E			
_	New	Old	Chg	New	Old	Chg	FY17E
Total weighted premium income (TWPI)	21,325	21,466	-1%	23,932	24,415	-2%	26,993
Annualized first-year premiums	4,219	4,360	-3%	4,817	5,219	-8%	5,563
Premiums and fee income	20,231	20,364	-1%	22,704	23,162	-2%	25,608
Net premiums and fee income	19,017	19,244	-1%	21,114	21,888	-4%	23,815
Net ins. & invest. contract benefits	(17,781)	(17,801)	0%	(19,214)	(19,700)	-2%	(21,434)
Total expenses	(4,155)	(4,234)	-2%	(4,603)	(4,815)	-4%	(5,180)
Commission expenses	(2,339)	(2,367)	-1%	(2,597)	(2,692)	-4%	(2,929)
Operating expenses	(1,816)	(1,867)	-3%	(2,006)	(2,123)	-6%	(2,251)
Underwriting profit	(2,919)	(2,790)	5%	(2,703)	(2,627)	3%	(2,798)
Investment return	8,283	8,042	3%	8,866	8,808	1%	9,625
Recurrent return	6,201	6,509	-5%	6,655	7,216	-8%	7,227
Realized & unreal. gains/(losses)	2,082	1,533	36%	2,210	1,592	39%	2,399
Other income and expenses	(220)	(165)	33%	(227)	(166)	37%	(232)
Profit/(loss) before tax	5,144	5,086	1%	<b>5,93</b> 6	6,016	-1%	6,595
Tax expense	(1,286)	(1,271)	1%	(1,484)	(1,504)	-1%	(1,649)
Attributable net profit	3,844	3,800	1%	4,439	4,499	-1%	4,934

Source: J.P. Morgan estimates

Figure 16: AIA Group: Profile of after-tax distributable earnings from in-force policies US\$ in millions



Source: Company reports.

AIA's projected after-tax distributable earnings from in-force policies from 2015 to 2019 is ~US\$13.7B (undiscounted basis). It means that, under the assumption of level earnings for the next five years, without new top-line growth, **the company's** 

annual earnings power from in-force policies is likely to be ~US\$2.7B. We believe the overall assumption supports high long-term cash flow visibility, given that: (1) the company's free cash flow is based on an 8.25% discount rate and 3.25% bond yield (weighted average), which is lower than the current interest rate environment and a relatively higher cost of capital; and (2) the company recognized the positive actuarial variances from in-force policies for the last couple of years.

#### **EV and NBV**

The company's record NBV growth momentum since 2010 has surprised the market almost every quarter with strong NBV growth. Given that the APE growth rate on an annual basis since 2010 was ~14% p.a., it would be fair to argue that the company's strong NBV growth of 20%+ y/y has been supported largely by product mix changes (or NBV margin enhancement). In our view, the company's record NBV margin above 50% (4Q14 NBV margin: 54.2%, +6.9%p y/y) will stay at current levels for a while. Although further NBV margin improvement would yield additional upside, our long-term NBV estimate models gradual NBV margin compression following the peak in 2015 from 50.8% in 2016 to 29.6% for the next 20 years, due to stricter regulations for better customer protection, rising competition and a more reserved outlook on new protection policies as the mortality/morbidity experience builds up.


Table 5: AIA Group: FY16E EV and NBV assumptions (FY15E-FY34E)

\$ in millions, %

Breakdown of EV	FY16E	Long-term NBV assumptions	
Adjusted net worth (ANW)	15,728	Blended annualized FYP growth (FY15E)	14.0%
Value of in-force business (VIF)	28,581	Blended annualized FYP growth (FY34E)	6.4%
New business value (NBV) (FY16E)	2,447	Blended new business margin (FY15E)	51.5%
Embedded value (= ANW + VIF)	44,309	Blended new business margin (FY34E)	29.6%

Source: J.P. Morgan estimates.

Figure 17: AIA Group: Volume growth and NBV margin projections



Source: J.P. Morgan estimates, Company reports.

In particular, we cut our long-term growth estimates for Korea, Singapore and Hong Kong following market saturation. Due to the outlook for healthcare/unit-linked product acceleration, we revise up our China long-term NBV margin outlook. The Malaysia number has been adjusted following the business integration with ING Malaysia (i.e., a high base).

Table 6: AIA Group: Summary of long-term NBV assumptions by country

% x

Hong Kong:	New (FY15E-FY34E)	Old (FY14E-FY33E)	China:	New (FY15E-FY34E)	Old (FY14E-FY33E)
Annualized FYP growth (FY14E) → (FY15E)	21.9%	21.9%	Annualized FYP growth (FY14E) → (FY15E)	24.9%	24.9%
Annualized FYP growth (FY33E) → (FY34E)	1.2%	10.0%	Annualized FYP growth (FY33E) → (FY34E)	11.2%	15.0%
New business margin (FY14E) → (FY15E)	60.6%	60.6%	New business margin (FY14E) → (FY15E)	57.7%	57.7%
New business margin (FY33E) → (FY34E)	41.3%	30.0%	New business margin (FY33E) → (FY34E)	37.6%	35.0%
Implied new business multiple	28x	31x	Implied new business multiple	42x	38x
Thailand:	New	Old	Korea:	New	Old
Annualized FYP growth (FY14E) → (FY15E)	1.2%	1.2%	Annualized FYP growth (FY14E) → (FY15E)	12.4%	12.4%
Annualized FYP growth (FY33E) → (FY34E)	9.7%	8.0%	Annualized FYP growth (FY33E) → (FY34E)	-13.8%	2.0%
New business margin (FY14E) → (FY15E)	53.9%	53.9%	New business margin (FY14E) → (FY15E)	28.7%	28.7%
New business margin (FY33E) → (FY34E)	31.8%	35.0%	New business margin (FY33E) → (FY34E)	4.0%	10.0%
Implied new business multiple	11x	15x	Implied new business multiple	7x	9x
Singapore:	New	Old	Other geographical markets:	New	Old
Annualized FYP growth (FY14E) → (FY15E)	22.3%	22.3%	Annualized FYP growth (FY14E) → (FY15E)	-1.9%	-1.9%
Annualized FYP growth (FY33E) → (FY34E)	-8.5%	15.0%	Annualized FYP growth (FY33E) → (FY34E)	5.6%	6.0%
New business margin (FY14E) → (FY15E)	66.7%	66.7%	New business margin (FY14E) → (FY15E)	26.2%	26.2%
New business margin (FY33E) → (FY34E)	22.0%	35.0%	New business margin (FY33E) → (FY34E)	11.4%	15.0%
Implied new business multiple	14x	34x	Implied new business multiple	15x	14x
Malaysia:	New	Old	Overall:	New	Old
Annualized FYP growth (FY14E) → (FY15E)	0.3%	0.3%	Annualized FYP growth (FY14E) → (FY15E)	14.0%	10.7%
Annualized FYP growth (FY33E) → (FY34E)	14.7%	15.0%	Annualized FYP growth (FY33E) → (FY34E)	6.4%	12.0%
New business margin (FY14E) → (FY15E)	45.0%	45.0%	New business margin (FY14E) → (FY15E)	51.5%	49.9%
New business margin (FY33E) → (FY34E)	40.6%	35.0%	New business margin (FY33E) → (FY34E)	29.6%	29.0%
Implied new business multiple	21x	41x	Implied new business multiple	22x	17x

Source: J.P. Morgan estimates.

## Solvency/free surplus

We revise our estimates of AIA's solvency/total free surplus, factoring in: (1) a larger-than-expected increase in shareholders' funds; (2) a lower capital consumption outlook for growth; and (3) a decreasing % of new business strain on total NBV. If the company's top-line growth per annum remains in the low teens, under the scenario of limited volatility in the long-term bond yield, its solvency ratio on a HKICO basis should stay at the  $\sim$ 400% level by 2017, in our view.

Table 7: AIA Group: Solvency ratio/total free surplus revisions

US\$ in millions, %, %p

	FY15E			FY16E			
	New	Old	Chg	New	Old	Chg	FY17E
Solvency margin ratio	409%	377%	31.8%p	401%	370%	31.5%	394%p
Total free surplus	9,865	6,791	45.3%	11,771	6,152	91.3%	14,574

Source: J.P. Morgan estimates.

## Investment Thesis, Valuation and Risks

### AlA Group Ltd (Overweight; Price Target: HK\$55.00)

#### **Investment Thesis**

AIA Group is the leading life insurer across Asia-ex, based on agency operations. For the last 90 years, the company has focused on managing its leading positions in Hong Kong, Singapore and Thailand. Low insurance penetration across the region, favorable demographic changes and household income growth (i.e., rising GDP per capita) in China and ASEAN countries are expected to support strong NBV growth momentum, with solid margins and volume growth as the market transforms into an agency-based protection-type market, where AIA has had a strong competitive edge for the last 90 years and the barriers to entry are very high. The high visibility of future cash flow generation from existing policies, a strong balance sheet and conservative actuarial assumptions should act as further share price drivers, in our view, particularly as the Asia-ex financial market shows higher volatility.

#### Valuation

We assign a Dec-15 price target of HK\$55. Our PT is derived via a multi-stage growth model to project NBV for each geographical market separately, which yields an implied blended P/EV of 2.1x and a blended new business multiple of 19x for the group.

	HK\$/share
Embedded value (November 30, 2016E)	28.72
Goodwill	30.71
New business value (FY16E)	1.59
New business multiple (x)	19x
Share price equivalent (November 30, 2016E)	59.43
Dec-15 price target	55.00

Source: J.P. Morgan estimates.

#### Risks to Rating and Price Target

Key downside risks include: (1) slowing turnaround momentum as AIA catches up with main rival Prudential; (2) longer-than-expected financial market or political volatility in Asia-ex or ASEAN countries; and (3) a longer-than-expected business turnaround in Malaysia following the ING Malaysia acquisition.




# **AIA Group Ltd: Summary of Financials**

SWP-Re Volitor fees   16,666   18,225   20,231   22,704   25,608   Shareholders' funds to insurance liab.   15,707   17,052   19,017   21,114   23,815   Solvency margin ratio (group operation)   433.0%   426.8%   41.0%   403.6%   397.1%   Net earned premiums   15,707   17,052   19,017   21,114   23,815   Sinsteporagin ratio (group operation)   433.0%   426.8%   41.0%   403.6%   397.1%   Net earned premiums   15,707   17,052   19,017   21,114   23,815   Sinsteporagin ratio (group operation)   433.0%   426.8%   41.0%   403.6%   397.1%   71.0%   41.0%	Income Statement (\$ in millions)	FY13	FY14	FY15E	FY16E	FY17E	Capital Strength	FY13	FY14	FY15E	FY16E	FY17E
Net earned premiums	GWP & Policy fees	16,666	18,225	20,231	22,704	25,608	Shareholders' funds to insurance liab.	22.1%	25.6%	24.9%	25.8%	
Total technical outgo	Net written premiums	15,707	17,052	19,017	21,114	23,815	Solvency margin ratio (group operation)	433.0%	426.8%	410.0%	403.6%	397.1%
Total expenses	Net earned premiums	15,707	17,052	19,017	21,114	23,815	First-year premiums	FY13	FY14	FY15E	FY16E	FY17E
Underwriting profit   C2,51   C3,527   C2,919   C2,703   C2,703	Total technical outgo	(14,487)	(16,804)	(17,781)	(19,214)	(21,434)	Single premiums	3,325	4,497	3,855	4,817	5,563
Net Investment Income   5,160   5,570   6,201   6,655   7,227   2,399   2,390   2,39	Total expenses	(3,471)	(3,775)	(4,155)	(4,603)	(5,180)	Regular premiums	2,815	3,087	3,834	4,335	5,006
Realized & unreal. Investment income   870   2,634   2,082   2,210   2,399   Loss ratio   92,278   98,578   93,578   91,078   90,078   10,078   10,078   11,078   1	Underwriting profit	(2,251)	(3,527)	(2,919)	(2,703)	(2,798)	AFYPs	3,341	3,700	4,219	4,817	5,563
Other income/expenses         (238)         (329)         (220)         (227)         (232)         Expense ratio         22.1%         21.9%         21.9%         21.8%         21.8%           Pre-tax profit         3,541         4,345         5,144         5,936         6,99         Combined ratio         114.3%         12.0%         114.5%         114.5%         114.5%         114.5%         114.5%         114.5%         114.5%         114.5%         114.5%         114.5%         114.5%         114.5%         114.5%         114.5%         114.5%         114.5%         114.5%         12.0%         5.7%         5.7%         5.7%         5.7%         Minorities         (25)         1(18)         1(14)         (13)         (12)         ROA         2.0%         6.0%         2.2%         2.2%         2.4%         2.4%         Net         Deposits         6.047         8718         FY15         FY16E         F	Net Investment Income	5,160	5,570	6,201	6,655	7,227	Profitability measure	FY13	FY14	FY15E	FY16E	FY17E
Pre-tax profit	Realized & unreal. Investment income	870	2,634	2,082	2,210	2,399	Loss ratio	92.2%	98.5%	93.5%	91.0%	90.0%
Tax         (692)         (877)         (1,286)         (1,484)         (1,649)         Total investment yield (incl. gains/losses)         5.0%         6.1%         5.7%         5.7%         5.7%           Minorities         (25)         (18)         (14)         (14)         (12)         ROA         2.0%         2.2%         2.2%         2.4%         2.4%           Net profit         2,824         3,507         3,844         4,439         9.717         PY18         PY18 </td <td>Other income/expenses</td> <td>(238)</td> <td>(332)</td> <td>(220)</td> <td>(227)</td> <td>(232)</td> <td>Expense ratio</td> <td>22.1%</td> <td>22.1%</td> <td>21.9%</td> <td>21.8%</td> <td>21.8%</td>	Other income/expenses	(238)	(332)	(220)	(227)	(232)	Expense ratio	22.1%	22.1%	21.9%	21.8%	21.8%
Minorities   C25   C18   C14   C13   C12   C13   C12   C13   C12   C13   C12   C13   C13	Pre-tax profit	3,541	4,345	5,144	5,936	6,595	Combined ratio	114.3%	120.7%	115.4%	112.8%	111.8%
Net profit   2,824   3,450   3,844   4,439   4,949	Tax	(692)	(877)	(1,286)	(1,484)	(1,649)	Total investment yield (incl. gains/losses)	5.0%			5.7%	
Part	Minorities	(25)	(18)	(14)	(13)			2.0%	2.2%	2.2%	2.4%	2.4%
Bonds   87,768   102,328   106,997   117,343   126,249   EPS   0.24   0.29   0.32   0.37   0.41     Equities   26,102   28,827   29,721   32,595   35,069   Y/Y   (6.3%)   22.2%   11.6%   15.7%   11.2%     Deposits   6,047   5,605   5,944   6,519   7,014   DPS   0.05   0.05   0.06   0.07   0.09   0.10     Other Investments   3,753   3,884   4,458   4,889   5,260   Payout ratio   23,3%   22.4%   23.1%   22.9%   23.7%     Total Investments   124,798   142,028   148,606   162,977   175,346   BVPS   2.06   2.57   2.68   2.97   3.28     Total Assets   147,402   166,919   177,194   190,428   215,659   No. of shares   12,006   12,008   11,964   11,964     Total insurance reserves   112,134   121,034   129,223   138,116   148,599   Group embedded value   2.82   3.09   3.37   3.70   4.09     Subordinated debts   1,950   2,934	Net profit	2,824	3,450	3,844	4,439	4,934	ROE	11.0%	12.4%	12.2%	13.1%	13.2%
Equities         26,102         28,827         29,721         32,595         35,609         Y/Y         (6.3%)         22.2%         11.6%         15.7%         11.2%           Deposits         6,047         5,605         5,944         6,519         7,014         DPS         0.05         0.06         0.07         0.09         0.10           Other Investments         3,753         3,884         4,848         4,889         5,600         BVPS         2.06         2.37         22.4%         23.7%         23.7%         20.01         2.37%         22.4%         23.7%         23.7%         20.01         2.37%         22.4%         2.31%         22.93         23.7%												
Deposits         6,047         5,605         5,944         6,519         7,014         DPS         0.05         0.06         0.07         0.09         0.10           Other Investments         3,753         3,884         4,458         4,889         5,260         Payout ratio         23.3%         22.4%         23.1%         22.9%         23.7%           Total Investments         124,798         142,028         148,600         162,977         175,346         BVPS         2.06         2.57         2.68         2.97         3.28           Total Assets         147,402         166,919         17,174         190,428         215,659         Mo.of shares         12,006         12,008         11,964	Bonds	87,768	102,328	106,997	117,343	126,249	EPS	0.24	0.29	0.32	0.37	0.41
Other Investments         3,753         3,884         4,458         4,889         5,260         Payout ratio         23.3%         22.4%         23.1%         22.9%         23.7%           Total Investments         124,798         142,028         148,606         162,977         175,346         BVPS         2.06         2.57         2.68         2.97         3.28           Total Assets         147,402         166,919         177,194         190,428         215,659         No. of shares         12,006         12,008         11,964         12,934	Equities	26,102	28,827	29,721	32,595	35,069	Y/Y	(6.3%)	22.2%	11.6%	15.7%	11.2%
Total Investments         124,798         142,028         148,606         162,977         75,346         BVPS         2.06         2.57         2.68         2.97         3.28           Total Assets         147,402         166,919         177,194         190,428         215,659         No. of shares         12,006         12,008         11,964	Deposits	-,-	,	5,944	,	, -						
Total Assets         147,402         166,919         177,194         199,428         215,659         No. of shares         12,006         12,008         11,964         11,964         11,964           Total insurance reserves         112,134         121,034         129,223         138,116         148,599         Group embedded value         2.82         3.09         3.37         3.70         4.09           Subordinated debts         1,950         2,934         2,934         2,934         1,954         1,950         3.77         4.09           Total liabilities         122,575         135,964         144,977         154,777         176,231         Y/Y         7.7%         9.8%         9.0%         9.8%         10.4%           Minority Interest         145         149         163         176         188         New business value         0.15         0.18         0.20         0.24           Shareholders' funds         24,682         30,806         32,054         35,475         39,244         14,7Y         15E,YY		-,	- ,	,	,							
Total insurance reserves         112,134         121,034         129,233         133,116         148,599         Group embedded value         2.82         3.09         3.37         3.70         4.09           Subordinated debts         1,950         2,934         2,934         2,934         2,934         Life operation embedded value         2.82         3.09         3.37         3.70         4.09           Total liabilities         122,575         135,964         144,977         154,777         176,231         Y/Y         7.7%         9.8%         9.0%         9.8%         10.4%           Minority Interest         145         149         163         176         188         New business value         0.12         0.15         0.18         0.20         0.24           Shareholders' funds         24,682         30,806         32,054         35,475         39,240         Y/Y         25.4%         23.8%         18.2%         12.6%         16.9%           Income Statement growth rates         13,YY         14,YY         15E, YY         15E, YY         17E, YY         YY         80         7.7%         16.6%         4.6%         9.7%         7.6%           Net arrend premiums         20.3%         8.6%         11.5%	Total Investments	124,798	142,028	148,606	162,977	175,346	BVPS	2.06	2.57	2.68	2.97	3.28
Subordinated debts         1,950         2,934         2,934         2,934         2,934         2,934         2,934         2,934         2,934         2,934         2,934         2,934         1,950         2,934         2,934         2,934         1,950         1,950         3.09         3.37         3.70         4.09           Total liabilities         122,575         135,964         144,977         154,777         176,231         Y/Y         7.7%         9.8%         9.0%         9.8%         10.4%           Minority Interest         145         149         163         176         188         New business value         0.15         0.18         0.20         0.24           Shareholders' funds         24,682         30,806         32,054         35,475         39,240         Y/Y         25.4%         23.8%         18.2%         12.6%         16.9%           Income Statement growth rates         13,YY         14,YY         15E, YY         15E, YY         17E, YY         YFE, YY         PY         25.4%         23.8%         18.2%         12.6%         16.9%         4.6%         9.7%         7.6%           GWP & policy fees         20.6%         8.6%         11.5%         11.0%         12.8% <t< td=""><td>Total Assets</td><td>147,402</td><td>166,919</td><td>, -</td><td>190,428</td><td>215,659</td><td>No. of shares</td><td>,</td><td>,</td><td>,</td><td>,</td><td>11,964</td></t<>	Total Assets	147,402	166,919	, -	190,428	215,659	No. of shares	,	,	,	,	11,964
Total liabilities         122,575         135,964         144,977         154,777         176,231         Y/Y         7.7%         9.8%         9.0%         9.8%         10.4%           Minority Interest         145         149         163         176         188         New business value         0.15         0.15         0.18         0.20         0.24           Shareholders' funds         24,682         30,806         32,054         35,475         39,240         Y/Y         25.4%         23.8%         18.2%         12.6%         16.9%           Income Statement growth rates         13,YY         14,YY         15E, YY         15E, YY         17E, YY         Prey Type, YY         Palaince sheet growth rates         13,YY         14,YY         15E, YY         17E, YY         Y/Y         18.8%         10.4%         4.6%         16.9%         16.9%         16.9%         16.9%         16.9%         7.6%         16.9%         16.9%         17.7%         16.6%         4.6%         9.7%         7.6%         16.4%         16.9%         17.9%         16.9%         16.9%         9.7%         7.6%         16.1%         16.9%         16.9%         17.6%         16.9%         16.9%         16.9%         7.6%         16.1%         16.1%<	Total insurance reserves	, -	,	-,	,	-,	•					
Minority Interest         145         149         163         176         188         New business value         0.12         0.15         0.18         0.20         0.24           Shareholders' funds         24,682         30,806         32,054         35,475         39,240         Y/Y         25.4%         23.8%         18.2%         12.6%         16.9%           Income Statement growth rates         13,Y/Y         14,Y/Y         15E, Y/Y         16E, Y/Y         1F, Y/Y </td <td></td> <td>,</td> <td>,</td> <td>,</td> <td>,</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>		,	,	,	,							
Shareholders' funds         24,682         30,806         32,054         35,475         39,240 yr/s         Y/Y         25.4%         23.8%         18.2%         12.6%         16.9%           Income Statement growth rates         13,Y/Y         14,Y/Y         15E, Y/Y         15E, Y/Y         17E, Y/Y         Balance sheet growth rates         13,Y/Y         14,Y/Y         15E, Y/Y         17E, Y/Y           GWP & policy fees         20.6%         9.4%         11.0%         12.2%         12.8%         Bonds         7.7%         16.6%         4.6%         9.7%         7.6%           Net earned premiums         20.3%         8.6%         11.5%         11.0%         12.8%         Equities         10.3%         10.4%         3.1%         9.7%         7.6%           Net Investment Income         15.6%         7.9%         11.3%         7.3%         8.6%         Deposits         (3.4%)         (7.3%)         6.1%         9.7%         7.6%           Total technical outgo         8.3%         10.0%         5.8%         8.1%         11.6%         Total investments         8.0%         13.8%         4.6%         9.7%         7.6%           Total expenses         16.4%         8.8%         10.1%         10.8%         12.5%	Total liabilities	,	,	,	,	,						
Income Statement growth rates         13,Y/Y         14,Y/Y         15E, Y/Y         16E, Y/Y         17E, Y/Y         Balance sheet growth rates         13,Y/Y         14,Y/Y         15E, Y/Y         16E, Y/Y         17E, Y/Y           GWP & policy fees         20.6%         9.4%         11.0%         12.2%         12.8%         Bonds         7.7%         16.6%         4.6%         9.7%         7.6%           Net earned premiums         20.3%         8.6%         11.5%         11.0%         12.8%         Equities         10.3%         10.4%         3.1%         9.7%         7.6%           Net Investment Income         15.6%         7.9%         11.3%         7.3%         8.6%         Deposits         (3.4%)         (7.3%)         6.1%         9.7%         7.6%           Total technical outgo         8.3%         16.0%         5.8%         8.1%         11.6%         Total investments         8.0%         13.8%         4.6%         9.7%         7.6%           Total expenses         16.4%         8.8%         10.1%         10.8%         12.5%         Total Assets         9.6%         13.2%         6.2%         7.5%         13.2%           Underwriting profit         (31.8%)         56.7%         (17.2%)         (7.4%) </td <td>Minority Interest</td> <td>145</td> <td>149</td> <td>163</td> <td>176</td> <td>188</td> <td>New business value</td> <td>0.12</td> <td>0.15</td> <td>0.18</td> <td>0.20</td> <td>0.24</td>	Minority Interest	145	149	163	176	188	New business value	0.12	0.15	0.18	0.20	0.24
GWP & policy fees         20.6%         9.4%         11.0%         12.2%         12.8%         Bonds         7.7%         16.6%         4.6%         9.7%         7.6%           Net earned premiums         20.3%         8.6%         11.5%         11.0%         12.8%         Equities         10.3%         10.4%         3.1%         9.7%         7.6%           Net Investment Income         15.6%         7.9%         11.3%         7.3%         8.6%         Deposits         (3.4%)         (7.3%)         6.1%         9.7%         7.6%           Total technical outgo         8.3%         16.0%         5.8%         8.1%         11.6%         Total investments         8.0%         13.8%         4.6%         9.7%         7.6%           Total expenses         16.4%         8.8%         10.1%         10.8%         12.5%         Total Assets         9.6%         13.2%         6.2%         7.5%         13.2%           Underwriting profit         (31.8%)         56.7%         (17.2%)         (7.4%)         3.5%         Total insurance reserves         12.8%         7.9%         6.8%         6.9%         7.6%           Pre-tax profit         (4.7%)         22.7%         18.4%         15.4%         11.1%         Tota	Shareholders' funds											
Net earned premiums         20.3%         8.6%         11.5%         11.0%         12.8%         Equities         10.3%         10.4%         3.1%         9.7%         7.6%           Net Investment Income         15.6%         7.9%         11.3%         7.3%         8.6%         Deposits         (3.4%)         (7.3%)         6.1%         9.7%         7.6%           Total technical outgo         8.3%         16.0%         5.8%         8.1%         11.6%         Total investments         8.0%         13.8%         4.6%         9.7%         7.6%           Total expenses         16.4%         8.8%         10.1%         10.8%         12.5%         Total Assets         9.6%         13.2%         6.2%         7.5%         13.2%           Underwriting profit         (31.8%)         56.7%         (17.2%)         (7.4%)         3.5%         Total insurance reserves         12.8%         7.9%         6.8%         6.9%         7.6%           Pre-tax profit         (4.7%)         22.7%         18.4%         15.4%         11.1%         Total liabilities         13.9%         10.9%         6.6%         6.8%         13.9%		,	, .	,	,			,	,	,		-
Net Investment Income         15.6%         7.9%         11.3%         7.3%         8.6%         Deposits         (3.4%)         (7.3%)         6.1%         9.7%         7.6%           Total technical outgo         8.3%         16.0%         5.8%         8.1%         11.6%         Total investments         8.0%         13.8%         4.6%         9.7%         7.6%           Total expenses         16.4%         8.8%         10.1%         10.8%         12.5%         Total Assets         9.6%         13.2%         6.2%         7.5%         13.2%           Underwriting profit         (31.8%)         56.7%         (17.2%)         (7.4%)         3.5%         Total insurance reserves         12.8%         7.9%         6.8%         6.9%         7.6%           Pre-tax profit         (4.7%)         22.7%         18.4%         15.4%         11.1%         Total liabilities         13.9%         10.9%         6.6%         6.8%         13.9%												
Total technical outgo         8.3%         16.0%         5.8%         8.1%         11.6%         Total investments         8.0%         13.8%         4.6%         9.7%         7.6%           Total expenses         16.4%         8.8%         10.1%         10.8%         12.5%         Total Assets         9.6%         13.2%         6.2%         7.5%         13.2%           Underwriting profit         (31.8%)         56.7%         (17.2%)         (7.4%)         3.5%         Total insurance reserves         12.8%         7.9%         6.8%         6.9%         7.6%           Pre-tax profit         (4.7%)         22.7%         18.4%         15.4%         11.1%         Total liabilities         13.9%         10.9%         6.6%         6.8%         13.9%	•						•					
Total expenses         16.4%         8.8%         10.1%         10.8%         12.5%         Total Assets         9.6%         13.2%         6.2%         7.5%         13.2%           Underwriting profit         (31.8%)         56.7%         (17.2%)         (7.4%)         3.5%         Total Insurance reserves         12.8%         7.9%         6.8%         6.9%         7.6%           Pre-tax profit         (4.7%)         22.7%         18.4%         15.4%         11.1%         Total liabilities         13.9%         10.9%         6.6%         6.8%         13.9%							•	, ,	٠,			
Underwriting profit         (31.8%)         56.7%         (17.2%)         (7.4%)         3.5%         Total insurance reserves         12.8%         7.9%         6.8%         6.9%         7.6%           Pre-tax profit         (4.7%)         22.7%         18.4%         15.4%         11.1%         Total liabilities         13.9%         10.9%         6.6%         6.8%         13.9%	Total technical outgo						Total investments					
Pre-tax profit (4.7%) 22.7% 18.4% 15.4% 11.1% Total liabilities 13.9% 10.9% 6.6% 6.8% 13.9%	Total expenses											
( '', '' '' '' '' '' '' '' '' '' '' '' ''	0.1	,		,	,							
Net profit (6.5%) 22.2% 11.4% 15.5% 11.2% Shareholders' funds (7.5%) 24.8% 4.1% 10.7% 10.6%	Pre-tax profit	(4.7%)						13.9%	10.9%			
(100) 200	Net profit	(6.5%)	22.2%	11.4%	15.5%	11.2%	Shareholders' funds	(7.5%)	24.8%	4.1%	10.7%	10.6%

Source: Company reports and J.P. Morgan estimates.





Analyst Certification: The research analyst(s) denoted by an "AC" on the cover of this report certifies (or, where multiple research analysts are primarily responsible for this report, the research analyst denoted by an "AC" on the cover or within the document individually certifies, with respect to each security or issuer that the research analyst covers in this research) that: (1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or issuers; and (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. For all Korea-based research analysts listed on the front cover, they also certify, as per KOFIA requirements, that their analysis was made in good faith and that the views reflect their own opinion, without undue influence or intervention.


#### **Important Disclosures**

- Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: AIA Group Ltd.
- Client/Non-Investment Banking, Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: AIA Group Ltd.
- Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from AIA Group Ltd.

Company-Specific Disclosures: Important disclosures, including price charts and credit opinion history tables, are available for compendium reports and all J.P. Morgan—covered companies by visiting <a href="https://jpmm.com/research/disclosures">https://jpmm.com/research/disclosures</a>, calling 1-800-477-0406, or e-mailing <a href="research.disclosure.inquiries@jpmorgan.com">research.disclosure.inquiries@jpmorgan.com</a> with your request. J.P. Morgan's Strategy, Technical, and Quantitative Research teams may screen companies not covered by J.P. Morgan. For important disclosures for these companies, please call 1-800-477-0406 or e-mail <a href="research.disclosure.inquiries@jpmorgan.com">research.disclosure.inquiries@jpmorgan.com</a>.

#### AIA Group Ltd (1299.HK, 1299 HK) Price Chart

Break in coverage May 07, 2013 - Jun 22, 2013.



Date	Rating	(HK\$)	(HK\$)
02-Dec-10	OW	22.90	26.00
18-Apr-11	OW	25.70	28.00
14-Jun-11	OW	28.15	30.00
02-Aug-11	OW	29.55	32.00
22-Aug-11	OW	25.40	31.00
14-Oct-11	OW	24.40	32.00
24-Feb-12	OW	28.30	34.00
16-Jul-12	OW	27.05	31.00
18-Oct-12	OW	29.80	34.00
27-Feb-13	OW	32.85	36.00
07-May-13	NR	34.65	
22-Jun-13	OW	32.50	40.00
27-Jul-13	OW	35.70	45.00
23-Jun-14	OW	38.30	46.00
27-Jul-14	OW	41.55	50.00
13-Jan-15	OW	43.90	51.00

Share Price Price Target

The chart(s) show J.P. Morgan's continuing coverage of the stocks; the current analysts may or may not have covered it over the entire period.

J.P. Morgan ratings or designations: OW = Overweight, N= Neutral, UW = Underweight, NR = Not Rated

#### Explanation of Equity Research Ratings, Designations and Analyst(s) Coverage Universe:

J.P. Morgan uses the following rating system: Overweight [Over the next six to twelve months, we expect this stock will outperform the average total return of the stocks in the analyst's (or the analyst's team's) coverage universe.] Neutral [Over the next six to twelve months, we expect this stock will perform in line with the average total return of the stocks in the analyst's (or the analyst's team's) coverage universe.] Underweight [Over the next six to twelve months, we expect this stock will underperform the average total return of the stocks in the analyst's (or the analyst's team's) coverage universe.] Not Rated (NR): J.P. Morgan has removed the rating and, if applicable, the price target, for this stock because of either a lack of a sufficient fundamental basis or for legal, regulatory or policy reasons. The previous rating and, if applicable, the price target, no longer should be relied upon. An NR designation is not a recommendation or a rating. In our Asia (ex-Australia) and U.K. small- and mid-cap equity research, each stock's expected total return is compared to the expected total return of a benchmark country market index, not to those analysts' coverage universe. If it does not appear



in the Important Disclosures section of this report, the certifying analyst's coverage universe can be found on J.P. Morgan's research website, www.jpmorganmarkets.com.

Coverage Universe: Kim, MW: AIA Group Ltd (1299.HK), China Life Insurance - A (601628.SS), China Life Insurance - H (2628.HK), China Pacific Insurance Group - A (601601.SS), China Pacific Insurance Group - H (2601.HK), China Taiping Insurance Holdings (0966.HK), Dongbu Insurance (005830.KS), Hanwha Life Insurance (088350.KS), Hyundai Marine & Fire Insurance (001450.KS), Korean Reinsurance Company (003690.KS), New China Life Insurance - A (601336.SS), New China Life Insurance - H (1336.HK), PICC Group (1339.HK), PICC Property and Casualty (2328.HK), Ping An Insurance Group - A (601318.SS), Ping An Insurance Group - H (2318.HK), Samsung Fire & Marine Insurance (000810.KS), Samsung Life Insurance (032830.KS), Tong Yang Life Insurance (082640.KS)

#### J.P. Morgan Equity Research Ratings Distribution, as of January 1, 2015

	Overweight	Neutral	Underweight
	(buy)	(hold)	(sell)
J.P. Morgan Global Equity Research Coverage	45%	43%	12%
IB clients*	56%	49%	33%
JPMS Equity Research Coverage	45%	48%	7%
IB clients*	75%	67%	52%

<sup>\*</sup>Percentage of investment banking clients in each rating category.

For purposes only of FINRA/NYSE ratings distribution rules, our Overweight rating falls into a buy rating category; our Neutral rating falls into a hold rating category; and our Underweight rating falls into a sell rating category. Please note that stocks with an NR designation are not included in the table above.

**Equity Valuation and Risks:** For valuation methodology and risks associated with covered companies or price targets for covered companies, please see the most recent company-specific research report at <a href="http://www.jpmorganmarkets.com">http://www.jpmorganmarkets.com</a>, contact the primary analyst or your J.P. Morgan representative, or email <a href="mailto:research.disclosure.inquiries@jpmorgan.com">research.disclosure.inquiries@jpmorgan.com</a>.

**Equity Analysts' Compensation:** The equity research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues.

**Registration of non-US Analysts:** Unless otherwise noted, the non-US analysts listed on the front of this report are employees of non-US affiliates of JPMS, are not registered/qualified as research analysts under NASD/NYSE rules, may not be associated persons of JPMS, and may not be subject to FINRA Rule 2711 and NYSE Rule 472 restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account.

#### **Other Disclosures**

J.P. Morgan ("JPM") is the global brand name for J.P. Morgan Securities LLC ("JPMS") and its affiliates worldwide. J.P. Morgan Cazenove is a marketing name for the U.K. investment banking businesses and EMEA cash equities and equity research businesses of JPMorgan Chase & Co. and its subsidiaries.

All research reports made available to clients are simultaneously available on our client website, J.P. Morgan Markets. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your sales representative.

**Options related research:** If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the Option Clearing Corporation's Characteristics and Risks of Standardized Options, please contact your J.P. Morgan Representative or visit the OCC's website at <a href="http://www.optionsclearing.com/publications/risks/riskstoc.pdf">http://www.optionsclearing.com/publications/risks/riskstoc.pdf</a>

#### **Legal Entities Disclosures**

U.S.: JPMS is a member of NYSE, FINRA, SIPC and the NFA. JPMorgan Chase Bank, N.A. is a member of FDIC. U.K.: JPMorgan Chase N.A., London Branch, is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and to limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from J.P. Morgan on request. J.P. Morgan Securities plc (JPMS plc) is a member of the London Stock Exchange and is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. Registered in England & Wales No. 2711006. Registered Office 25 Bank Street, London, E14 5JP. South Africa: J.P. Morgan Equities South Africa Proprietary Limited is a member of the Johannesburg Securities Exchange and is regulated by the Financial Services Board. Hong Kong: J.P. Morgan Securities (Asia Pacific) Limited (CE number AAJ321) is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission in Hong Kong and/or J.P. Morgan Broking (Hong Kong) Limited (CE number AAB027) is regulated by the Securities and Futures Commission in Hong Kong, Korea: J.P. Morgan Securities (Far East) Ltd, Seoul Branch, is regulated by the Korea Financial Supervisory Service. Australia: J.P. Morgan Australia Limited (JPMAL) (ABN 52 002 888 011/AFS Licence No: 238188) is regulated by ASIC and J.P. Morgan Securities Australia Limited (JPMSAL) (ABN 61 003 245 234/AFS Licence No: 238066) is regulated by ASIC and is a Market, Clearing and Settlement Participant of ASX Limited and CHI-X. Taiwan: J.P.Morgan Securities (Taiwan) Limited is a participant of the Taiwan Stock Exchange (company-type) and regulated by the Taiwan Securities and Futures Bureau. India: J.P. Morgan India Private Limited (Corporate Identity Number - U67120MH1992FTC068724), having its registered office at J.P. Morgan Tower, Off. C.S.T. Road, Kalina, Santacruz - East, Mumbai – 400098, is a member of the National Stock Exchange of India Limited (SEBI Registration Number - INB 230675231/INF 230675231/INE 230675231) and Bombay Stock Exchange Limited (SEBI Registration Number - INB 010675237/INF 010675237) and is regulated by Securities and

Exchange Board of India. Telephone: 91-22-6157 3000, Facsimile: 91-22-6157 3990 and Website: www.jpmipl.com. For non local research reports, this material is not distributed in India by J.P. Morgan India Private Limited. Thailand: This material is issued and distributed in Thailand by JPMorgan Securities (Thailand) Ltd., which is a member of the Stock Exchange of Thailand and is regulated by the Ministry of Finance and the Securities and Exchange Commission and its registered address is 3rd Floor, 20 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Indonesia: PT J.P. Morgan Securities Indonesia is a member of the Indonesia Stock Exchange and is regulated by the OJK a.k.a. BAPEPAM LK. Philippines: J.P. Morgan Securities Philippines Inc. is a Trading Participant of the Philippine Stock Exchange and a member of the Securities Clearing Corporation of the Philippines and the Securities Investor Protection Fund. It is regulated by the Securities and Exchange Commission. Brazil: Banco J.P. Morgan S.A. is regulated by the Comissao de Valores Mobiliarios (CVM) and by the Central Bank of Brazil. Mexico: J.P. Morgan Casa de Bolsa, S.A. de C.V., J.P. Morgan Grupo Financiero is a member of the Mexican Stock Exchange and authorized to act as a broker dealer by the National Banking and Securities Exchange Commission. Singapore: This material is issued and distributed in Singapore by or through J.P. Morgan Securities Singapore Private Limited (JPMSS) [MCI (P) 199/03/2014 and Co. Reg. No.: 199405335R] which is a member of the Singapore Exchange Securities Trading Limited and is regulated by the Monetary Authority of Singapore (MAS) and/or JPMorgan Chase Bank, N.A., Singapore branch (JPMCB Singapore) which is regulated by the MAS. This material is provided in Singapore only to accredited investors, expert investors and institutional investors, as defined in Section 4A of the Securities and Futures Act, Cap. 289. Recipients of this document are to contact JPMSS or JPMCB Singapore in respect of any matters arising from, or in connection with, the document. Japan: JPMorgan Securities Japan Co., Ltd. is regulated by the Financial Services Agency in Japan. Malaysia: This material is issued and distributed in Malaysia by JPMorgan Securities (Malaysia) Sdn Bhd (18146-X) which is a Participating Organization of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission in Malaysia. Pakistan: J. P. Morgan Pakistan Broking (Pvt.) Ltd is a member of the Karachi Stock Exchange and regulated by the Securities and Exchange Commission of Pakistan. Saudi Arabia: J.P. Morgan Saudi Arabia Ltd. is authorized by the Capital Market Authority of the Kingdom of Saudi Arabia (CMA) to carry out dealing as an agent, arranging, advising and custody, with respect to securities business under licence number 35-07079 and its registered address is at 8th Floor, Al-Faisaliyah Tower, King Fahad Road, P.O. Box 51907, Riyadh 11553, Kingdom of Saudi Arabia. Dubai: JPMorgan Chase Bank, N.A., Dubai Branch is regulated by the Dubai Financial Services Authority (DFSA) and its registered address is Dubai International Financial Centre - Building 3, Level 7, PO Box 506551, Dubai, UAE.

#### **Country and Region Specific Disclosures**

U.K. and European Economic Area (EEA): Unless specified to the contrary, issued and approved for distribution in the U.K. and the EEA by JPMS plc. Investment research issued by JPMS plc has been prepared in accordance with JPMS plc's policies for managing conflicts of interest arising as a result of publication and distribution of investment research. Many European regulators require a firm to establish, implement and maintain such a policy. This report has been issued in the U.K. only to persons of a kind described in Article 19 (5), 38, 47 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (all such persons being referred to as "relevant persons"). This document must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is only available to relevant persons and will be engaged in only with relevant persons. In other EEA countries, the report has been issued to persons regarded as professional investors (or equivalent) in their home jurisdiction. Australia: This material is issued and distributed by JPMSAL in Australia to "wholesale clients" only. This material does not take into account the specific investment objectives, financial situation or particular needs of the recipient. The recipient of this material must not distribute it to any third party or outside Australia without the prior written consent of JPMSAL. For the purposes of this paragraph the term "wholesale client" has the meaning given in section 761G of the Corporations Act 2001. Germany: This material is distributed in Germany by J.P. Morgan Securities plc, Frankfurt Branch and J.P.Morgan Chase Bank, N.A., Frankfurt Branch which are regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht. Hong Kong: The 1% ownership disclosure as of the previous month end satisfies the requirements under Paragraph 16.5(a) of the Hong Kong Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission. (For research published within the first ten days of the month, the disclosure may be based on the month end data from two months prior.) J.P. Morgan Broking (Hong Kong) Limited is the liquidity provider/market maker for derivative warrants, callable bull bear contracts and stock options listed on the Stock Exchange of Hong Kong Limited. An updated list can be found on HKEx website: http://www.hkex.com.hk. Japan: There is a risk that a loss may occur due to a change in the price of the shares in the case of share trading, and that a loss may occur due to the exchange rate in the case of foreign share trading. In the case of share trading, JPMorgan Securities Japan Co., Ltd., will be receiving a brokerage fee and consumption tax (shouhizei) calculated by multiplying the executed price by the commission rate which was individually agreed between JPMorgan Securities Japan Co., Ltd., and the customer in advance. Financial Instruments Firms: JPMorgan Securities Japan Co., Ltd., Kanto Local Finance Bureau (kinsho) No. 82 Participating Association / Japan Securities Dealers Association, The Financial Futures Association of Japan, Type II Financial Instruments Firms Association and Japan Investment Advisers Association. Korea: This report may have been edited or contributed to from time to time by affiliates of J.P. Morgan Securities (Far East) Ltd, Seoul Branch. Singapore: JPMSS and/or its affiliates may have a holding in any of the securities discussed in this report; for securities where the holding is 1% or greater, the specific holding is disclosed in the Important Disclosures section above. Taiwan: This material is issued and distributed in Taiwan by J.P. Morgan Securities (Taiwan Limited). India: For private circulation only, not for sale. Pakistan: For private circulation only, not for sale. New Zealand: This material is issued and distributed by JPMSAL in New Zealand only to persons whose principal business is the investment of money or who, in the course of and for the purposes of their business, habitually invest money. JPMSAL does not issue or distribute this material to members of "the public" as determined in accordance with section 3 of the Securities Act 1978. The recipient of this material must not distribute it to any third party or outside New Zealand without the prior written consent of JPMSAL. Canada: The information contained herein is not, and under no circumstances is to be construed as, a prospectus, an advertisement, a public offering, an offer to sell securities described herein, or solicitation of an offer to buy securities described herein, in Canada or any province or territory thereof. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the dealer registration requirement in the relevant province or territory of Canada in which such offer or sale is made. The information contained herein is under no circumstances to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. To the extent that the information contained herein references securities of an issuer incorporated, formed or created under the laws of Canada or a province or territory of Canada, any trades in such securities must be conducted through a dealer registered in Canada. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed judgment upon these materials, the information contained herein or the merits of the securities described herein, and any representation to the contrary is an offence. Dubai: This report has been issued to persons regarded as professional clients as defined under the DFSA rules. Brazil: Ombudsman J.P. Morgan: 0800-7700847 / ouvidoria.jp.morgan@jpmorgan.com.

General: Additional information is available upon request. Information has been obtained from sources believed to be reliable but JPMorgan Chase & Co. or its affiliates and/or subsidiaries (collectively J.P. Morgan) do not warrant its completeness or accuracy except with respect to any disclosures relative to JPMS and/or its affiliates and the analyst's involvement with the issuer that is the subject of the research. All pricing is as of the close of market for the

Asia Pacific Equity Research 02 March 2015

MW Kim (852) 2800-8517 mw.kim@jpmorgan.com



securities discussed, unless otherwise stated. Opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Past performance is not indicative of future results. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein. JPMS distributes in the U.S. research published by non-U.S. affiliates and accepts responsibility for its contents. Periodic updates may be provided on companies/industries based on company specific developments or announcements, market conditions or any other publicly available information. Clients should contact analysts and execute transactions through a J.P. Morgan subsidiary or affiliate in their home jurisdiction unless governing law permits otherwise.

"Other Disclosures" last revised November 29, 2014.

Copyright 2015 JPMorgan Chase & Co. All rights reserved. This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan.